Literature DB >> 17328145

Beta3-adrenergic eNOS stimulation in left ventricular murine myocardium.

Klara Brixius1, Wilhelm Bloch, Christoph Ziskoven, Birgit Bölck, Andreas Napp, Christian Pott, Dirk Steinritz, Maria Jiminez, Klaus Addicks, Jean-Paul Giacobino, Robert H G Schwinger.   

Abstract

This study investigates mechanisms underlying beta3-adrenergic activation of the endothelial nitric oxide synthase (eNOS) in myocardial tissue of wild-type (WT) and beta3-adrenoceptor knockout (beta3-KNO) mice, in the absence and presence of BRL 37344 (BRL), the preferential beta3-adrenoceptor selective agonist. Nitric oxide (NO)-liberation was measured after the application of BRL (10 micromol/L), using fluorescence dye diaminofluorescein (DAF), in left ventricular cardiac preparations. Phosphorylation of eNOSSer1177, eNOSThr495, eNOSSer114, and eNOS translocation, and alterations of 8-isoprostaglandin F2alpha (a parameter for reactive oxygen radical generation), after application of BRL (10 micromol/L), were studied using immunohistochemical stainings in isolated, electrically stimulated (1 Hz) right atrial (RA) and left ventricular (LV) myocardium. An increased NO release after BRL application (10 micromol/L) was observed in the RA and LV myocardial tissue of WT mice, but not in beta3-KNO mice. This NO liberation in WT mice was paralleled by an increased eNOSSer1177, but not eNOSThr495, phosphorylation. A cytosolic eNOS translocation was observed after the application of BRL (10 micromol/L) only in the RA myocardial tissue of WT mice. A BRL (10 micromol/L)-dependent increase in eNOSSer114 phosphorylation was observed only in the LV myocardial tissue of WT mice; this was paralleled by an increase in 8-isoprostaglandin F2alpha. In murine myocardium, 3 beta3-adrenoceptor-dependent activation pathways for eNOS exist (i.e., a translocation and phosphorylation of eNOSSer1177 and eNOSSer114). These pathways are used in a regional-dependent manner. beta3-adrenergic oxygen-derived free radical production might be important in situations of enhanced beta3-adrenoceptor activation, as has been described in human heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17328145     DOI: 10.1139/y06-033

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  15 in total

1.  Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: Confronting the maze.

Authors:  Vijay Sharma; John H McNeill
Journal:  World J Cardiol       Date:  2011-09-26

2.  Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase.

Authors:  Xiaolin Niu; Vabren L Watts; Oscar H Cingolani; Vidhya Sivakumaran; Jordan S Leyton-Mange; Carla L Ellis; Karen L Miller; Konrad Vandegaer; Djahida Bedja; Kathleen L Gabrielson; Nazareno Paolocci; David A Kass; Lili A Barouch
Journal:  J Am Coll Cardiol       Date:  2012-05-29       Impact factor: 24.094

3.  Increased Ca2+ sensitivity and protein expression of SERCA 2a in situations of chronic beta3-adrenoceptor deficiency.

Authors:  Christoph Ziskoven; Sabrina Grafweg; Birgit Bölck; Rudolf J Wiesner; Maria Jimenez; Jean-Paul Giacobino; W Bloch; Robert H G Schwinger; Klara Brixius
Journal:  Pflugers Arch       Date:  2006-09-22       Impact factor: 3.657

Review 4.  Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.

Authors:  An L Moens; Ronghua Yang; Vabren L Watts; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2010-02-23       Impact factor: 5.000

5.  Specificity evaluation of antibodies against human β3-adrenoceptors.

Authors:  Hana Cernecka; Peter Ochodnicky; Wouter H Lamers; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-06-12       Impact factor: 3.000

6.  Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor.

Authors:  An L Moens; Jordan S Leyton-Mange; Xiaolin Niu; Ronghua Yang; Oscar Cingolani; Elisabeth K Arkenbout; Hunter C Champion; Djahida Bedja; Kathleen L Gabrielson; Juan Chen; Yong Xia; Ashley B Hale; Keith M Channon; Marc K Halushka; Norman Barker; Floris L Wuyts; Pawel M Kaminski; Michael S Wolin; David A Kass; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

Review 7.  A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling.

Authors:  Jihong Yang; Yufeng Liu; Xiaohui Fan; Zheng Li; Yiyu Cheng
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

8.  Anti-hypertrophic and anti-oxidant effect of beta3-adrenergic stimulation in myocytes requires differential neuronal NOS phosphorylation.

Authors:  Vabren L Watts; Fernando M Sepulveda; Oscar H Cingolani; Alice S Ho; Xiaolin Niu; Rosa Kim; Karen L Miller; Koenraad Vandegaer; Djahida Bedja; Kathleen L Gabrielson; Gerald Rameau; Brian O'Rourke; David A Kass; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2013-05-02       Impact factor: 5.000

9.  PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation.

Authors:  Dong I Lee; Susan Vahebi; Carlo Gabriele Tocchetti; Lili A Barouch; R John Solaro; Eiki Takimoto; David A Kass
Journal:  Basic Res Cardiol       Date:  2010-01-27       Impact factor: 17.165

10.  Total beta-adrenoceptor knockout slows conduction and reduces inducible arrhythmias in the mouse heart.

Authors:  Florian Stöckigt; Klara Brixius; Lars Lickfett; René Andrié; Markus Linhart; Georg Nickenig; Jan Wilko Schrickel
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.